William Snider - 09 Jun 2026 Form 4 Insider Report for HARVARD BIOSCIENCE INC (HBIO)

Reporting relationship: Director
Issuer ticker: HBIO
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2026, 12:56:20 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ William Snider

Key filing fact

William Snider filed Form 4 for HARVARD BIOSCIENCE INC (HBIO) on 11 Jun 2026.

Key facts

This page summarizes William Snider's Form 4 filing for HARVARD BIOSCIENCE INC (HBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jun 2026, 12:56.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001340831 Primary reporting owner

Snider William

Relationship: Director
Address: C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON
Signature: /s/ William Snider
Signature date: 11 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HBIO transaction

Common Stock

Award

Transaction value
Shares: +16,556
Change %: +52%
Price: $0.000000^*
Shares after: 48,556
Date: 09 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Footnote F2

Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.

Footnote F3

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.